Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone
Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone 05 July 2024, Volume 22, article number 630, (2024) Matthias Löhn and Klaus Josef Wirth Journal of Translational Medicine Abstract Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating disease with a broad overlap of symptomatology […]
German Journal of Veterinary Research Current pharmacotherapeutic properties of low-dose naltrexone therapy in humans and possible therapeutic and prophylactic indications in cats and dogs
German Journal of Veterinary Research Current pharmacotherapeutic properties of low-dose naltrexone therapy in humans and possible therapeutic and prophylactic indications in cats and dogs Reza G Marangaloo et al., March 2024 German Journal of Veterinary Research 4(1):39-45 Naltrexone was first developed in 1963 as an opioid antagonist for therapeutic use in opioid-dependent individuals (alcohol, narcotics, and […]
Neuroprotective effects of naltrexone in a mouse model of post-traumatic seizures
Neuroprotective effects of naltrexone in a mouse model of post-traumatic seizures Saul Rodriguez et al. Nature. 12th June 2024 https://www.nature.com/articles/s41598-024-63942-8 Abstract Traumatic Brain Injury (TBI) induces neuroinflammatory response that can initiate epileptogenesis, which develops into epilepsy. Recently, we identified anti-convulsive effects of naltrexone, a mu-opioid receptor (MOR) antagonist, used to treat drug addiction. While blocking […]
Current pharmacotherapeutic properties of low-dose naltrexone therapy in humans and possible therapeutic and prophylactic indications in cats and dogs
Reza G. Marangaloo et al., German Journal of Veterinary Research, 20th February 2024 https://gmpc-akademie.de/articles/1709702482_2024_4_1_0070_GJVR_Marangaloo.pdf Abstract Naltrexone was first developed in 1963 as an opioid antagonist for therapeutic use in opioid-dependent individuals (alcohol, narcotics, and tobacco) with a 50 mg/day dose approved by the Food and Drug Administration (FDA). In 1985, Dr. Bernard Bihari explained that when […]
Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia
Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia Hiten Naik et al. Online issue publication May 13, 2024 Abstract Introduction A significant proportion of individuals suffering from post COVID-19 condition (PCC, also known as long COVID) can present with persistent, disabling fatigue similar to myalgic encephalomyelitis/chronic […]
Low-dose Naltrexone (LDN) extends healthspan and lifespan in C. elegans via SKN-1 activation

Low-dose Naltrexone (LDN) extends healthspan and lifespan in C. elegans via SKN-1 activation Weisha Li, et al. Open Access Published:May 08, 2024 https://www.cell.com/iscience/fulltext/S2589-0042(24)01171-4 Highlights: • Low-dose naltrexone (LDN) extends healthspan and lifespan in C. elegans. • LDN promotes nuclear translocation of transcription factor SKN-1. • Lifespan and healthspan extension of LDN depends on SKN-1. • LDN activates the oxidative […]
Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19
Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19 Anar Isman, Andy Nyquist, Bailey Strecker, Girish Harinath, Virginia Lee, Xingyu Zhang, Sajad Zalzala Brain Behav Immun Health, 2024 Feb 1:36:100733. https://pubmed.ncbi.nlm.nih.gov/38352659/ Abstract A subset of patients experiences persistent fatigue symptoms after COVID-19, and patients may develop long COVID, which […]
Low-Dose Naltrexone for Excoriation Disorder
Low-Dose Naltrexone for Excoriation Disorder Kevin Varghese, Xiaofeng Yan, Fei Cao Cureus, 2024 Mar 1;16(3):e55336. https://pubmed.ncbi.nlm.nih.gov/38559544/ Abstract Excoriation (skin-picking) disorder (ED) is a condition characterized by the repeated compulsion to pick at the skin, causing physical trauma and psychiatric distress. Patients often desire to cease skin-picking behavior but are unable to do so. Multiple treatment […]
Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy
Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy Marianna Ciwun, Anna Tankiewicz-Kwedlo, Dariusz Pawlak Cancers (Basel), 2024 Mar 21;16(6):1240. https://pubmed.ncbi.nlm.nih.gov/38539570/ Abstract Naltrexone (NTX) is a non-selective antagonist of opioid receptors, primarily used in the therapy of opioid and alcohol dependence. Low-dose naltrexone (LDN) exhibits antagonistic action against the opioid growth factor receptor (OGFr), whose […]
Low-Dose Naltrexone Improves post-COVID-19 Condition Symptoms
Low-Dose Naltrexone Improves post-COVID-19 Condition Symptoms Leonardo Tamariz, Elizabeth Bast, Nancy Klimas, Ana Palacio Clin Ther, . 23rd Jan 2024:S0149-2918(24)00003-1. https://pubmed.ncbi.nlm.nih.gov/38267326/ Abstract Purpose: Treatments for myalgic encephalomyelitis and chronic fatigue syndrome can be adapted for post-COVID-19 condition. Our aim was to compare treatments in patients from our post-COVID-19 clinic. Methods: We conducted a retrospective cohort study […]